(Sharecast News) - Clinical artificial intelligence (AI) company Sensyne Health announced on Monday that its 'CVm-Health+' app is to be used by the University of Oxford in its 'FACTS' clinical study evaluating the feasibility and acceptability of new point-of-care tests for regular asymptomatic Covid-19 testing in the community.
The AIM-traded firm said the FACTS study is one of the three university pilot projects established by the UK Department for Health and Social Care, and Public Health England.
It said the CVm-Health+ app would be used to provide access to study information and links to training materials, and record health status and test result data for students and staff with consent.
The app would also capture a time-stamped photograph of the point-of-care test result each time an individual performs a test, to provide independent classification.
"The Covid-19 pandemic is forcing all organisations to understand and adapt to infection risk," said chief executive officer Lord Drayson.
"Remote health monitoring software and the analysis of health data using clinical AI is already helping to mitigate the effects of Covid-19 in the healthcare sector and we are pleased that CVm-Health is being used for another clinical study of national importance."
At 1143 GMT, shares in Sensyne Health were up 7.08% at 135.66p.
14 Jan 2022 09:50
Sensyne shares drop as it seeks shareholder funds to continue trading
Sensyne shares drop as it seeks shareholder funds to continue trading
Read more